Introduction
One of the benzodiazepines that is used in the treatment of anxiety disorders. It is a Schedule IV drug in the U.S. and Canada and under the Convention on Psychotropic Substances. It is a intermediate-acting benzodiazepine.
Uses
Tarbo 3 mg is a short-acting benzodiazepine with intermediate onset commonly used to treat panic disorders and severe anxiety.
For the short-term treatment of insomnia, short-term treatment of anxiety or panic attacks, if a benzodiazepine is required, and the alleviation of the symptoms of alcohol- and opiate-withdrawal.
Associated Conditions
Pharmacodynamics
Tarbo 3 mg is a lipophilic, long-acting benzodiazepine and with sedative, hypnotic, anxiolytic and skeletal muscle relaxant properties. It does not possess any antidepressant qualities. Tarbo 3 mg, like other benzodiazepines, presents a risk of abuse, misuse, and dependence. According to many psychiatric experts, Tarbo 3 mg has a greater abuse potential than other benzodiazepines because of fast resorption and rapid onset of action.
Mechanism of Action
Tarbo 3 mg binds to the GABA-A receptor producing a conformational change and potentiating its inhibitory effects. Other neurotransmitters are not influenced.
Absorption
Bioavailability is 84% following oral administration. The time to peak plasma level is 1 - 4 hours. Tarbo 3 mg is generally well absorbed after oral administration.
Volume of Distribution
1.56 L/kg
Protein Binding
70%
Route of Elimination
Urine (69%), as metabolites
Half Life
10-20 hours
Clearance
0.82 mL/min/kg.
Food Interactions
- Avoid alcohol. Ingesting alcohol may increase the sedative and CNS depressant effects of bromazepam.
- Take with or without food. Taking bromazepam with food may reduce its Cmax and AUC.
Dosage
In severe cases, especially in hospital: 6-12 mg 2 or 3 times daily. The overall treatment generally should not be more than 8-12 weeks. In certain cases extension beyond the maximum treatment period may be necessary; if so, it should be taken with re-evaluation of the patient's status with special expertise.
Elderly and debilitated patients: Elderly patients and those with impaired hepatic functions require lower doses.
Children: Tarbo 3 mg is usually not indicated in children, but if the physician feels bromazepam treatment is appropriate, then the dose should be adjusted to their low bodyweight (about 0.1-0.3 mg/kg bodyweight)
